PF-06865571 free base · Synonyms: Ervogastat

PF-06865571 is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor.

For research use only. Not for human or veterinary use.

Target DGAT2

Research area Metabolic & Endocrine Diseases

Purity >98% Stock Inquire

Data Sheet SDS COA

PF-06865571 structure

CAS No.: 2186700-33-2

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 585.00	BP-02244-250mg	In stock	Get quote
500 mg	USD 850.00	BP-02244-500mg	In stock	Get quote
1 g	USD 1,550.00	BP-02244-1g	In stock	Get quote
2 g	USD 2,400.00	BP-02244-2g	In stock	Get quote
5 g	USD 3,900.00	BP-02244-5g	In stock	Get quote
10 g	Inquire	BP-02244-10g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

PF-06865571 (Ervogastat) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. PF-06865571 reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).

Biological activity

Ervogastat is a DGAT2 inhibitor that can be used in studies related to non-alcoholic steatohepatitis (NASH).

Specifications

MW (average): 407.4225
Formula: C₂₁H₂₁N₅O₄
CAS No.: 2186700-33-2
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO、Ethanol

In vitro: DMSO : 81 mg/mL Ethanol : 5 mg/mL

Documents

References

[1]. Futatsugi, Kentaro et al. “Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.” Journal of medicinal chemistry vol. 65,22 (2022): 15000-15013.